What is GPC3?
GPC3 (Glypican-3) is a protein attached to the surface of cells. In healthy adults, it is present at very low levels in the liver, but it is overexpressed in many liver cancers, especially Hepatocellular carcinoma (HCC).
Because of this, GPC3 has become important for:
Diagnosing liver cancer
Predicting prognosis
Developing targeted therapies
Why is GPC3 important in liver cancer?
Approximately 70–80% of hepatocellular carcinomas express GPC3, while normal liver tissue and most benign liver lesions do not.
This makes GPC3 useful for distinguishing:
HCC from normal liver tissue
HCC from benign liver tumors
HCC from regenerative nodules in cirrhosis
However, not every HCC is GPC3-positive, so doctors do not rely on this marker alone.
How is GPC3 tested?
1. Tissue biopsy (most common)
A pathologist stains the tumor tissue for GPC3 using immunohistochemistry (IHC).
Results:
Positive: Supports the diagnosis of HCC.
Negative: Does not rule out HCC, since some tumors lack GPC3 expression.
2. Blood test
Researchers have studied circulating GPC3 in blood, but it is not widely used in routine clinical practice because its accuracy is less established than tissue testing.
Does GPC3 mean the cancer is more aggressive?
Generally, yes.
Higher GPC3 expression has been associated with:
Larger tumors
Poorer differentiation
Increased risk of recurrence
Shorter overall survival
However, prognosis depends on many factors, including:
Tumor size and number
Presence of vascular invasion
Liver function
Stage at diagnosis
Response to treatment
Can GPC3 be targeted for treatment?
Yes. GPC3 is an attractive target because it is largely absent from normal adult tissues.
Several investigational approaches are being studied:
CAR T-cell therapy directed against GPC3
Bispecific antibodies
Monoclonal antibodies
Cancer vaccines
Antibody-drug conjugates
Early clinical trials have shown encouraging activity in some patients, but no GPC3-targeted therapy is currently a standard approved treatment for HCC in most countries. Research is ongoing.
Relationship with AFP
Doctors often use GPC3 together with AFP (alpha-fetoprotein) because they provide complementary information.
| Marker | Use |
|---|---|
| GPC3 | Mainly tissue diagnosis; target for experimental therapies |
| AFP | Blood marker used for diagnosis, prognosis, and monitoring treatment response |
Some patients with normal AFP still have GPC3-positive tumors.
Current standard treatments for HCC
Treatment depends on the stage of disease and liver function, and may include:
Surgical removal of the tumor
Liver transplantation (for selected patients)
Local ablation
Transarterial chemoembolization (TACE)
Radiation therapy
Immunotherapy (such as checkpoint inhibitors)
Targeted drugs (such as tyrosine kinase inhibitors)
GPC3 testing may be relevant if a patient is being considered for a clinical trial of GPC3-directed therapy.
You May Like: